chevron_leftBack
As of 13 June 2026, Apimeds Pharmaceuticals US, Inc. has a market cap of $23.64M USD, ranking #35904 globally and #4910 in the United States.
It ranks #3226 in the Healthcare sector, and #625 in the Biotechnology industry.
Key Stats
Market Cap
$23.64MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Vinod Menon
open_in_new
Founded
2020
IPO
09 May 2025
Website
mindwavedao.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | 15% | 38% | 15% | -42% | -30% |
News
Loading...
APUS Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
APUS
Apimeds Pharmaceuticals Us Inc
ISIN: US03771D1028
Shares Out.:
Shares Outstanding:
15.091M1
Shares Float:
5.632M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.88 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
771K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
676K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
117K%
|
-
|
|
NYSE: IQV
|
$26.3B
111K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
106K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
77K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
202K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
190K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
179K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
179K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
119K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
109K%
|
-
|
chevron_leftBack